Drug Trial Radar · NCT01543321
Xenazine in Late Dyskinetic Syndrome With Neuroleptics
Last checked: Nov 20, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
May 14, 2012
Primary completion
May 18, 2017
Study completion Aug 2017
Sponsor
- Lead sponsor
- Centre Hospitalier Universitaire, AmiensAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 2, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Late dyskinetic syndrome with neuroleptics, or tardive dyskinesia, is the appearance of abnormal involuntary movements (AIM) in patients treated with antipsychotics for at least three months. This important public health issue arises for 15-20% of patients treated with neuroleptics, the most prescribed psychotropic drugs in mental disorders in France, and seriously impacts the patients' quality of life. In over 50% of cases, it is irreversible-that is to say that he will persist despite discontinuation of the offending drug. Risk factors have been described: the age and female gender are established, a higher dosage of antipsychotic, a long-term treatment, a psychiatric condition other than schizophrenia are likely risk factors, intermittent treatment, previous acute dyskinesia, neuroleptics or powerful, longer term use of corrective treatments including anticholinergics are still discussed. Apart from preventive treatment, which consists in using antipsychotics as being coerced, support is disappointing: the etiological treatment, which is to stop the offending antipsychotic, is effective only in less than 50% of cases, the syndrome is most often late irreversible. Must still have the possibility to interrupt the treatment, which is usually impossible in the risk of decompensation of the mental illness for which the neuroleptic was prescribed. Remains symptomatic treatment: functional neurosurgery is only for extreme cases, because it is not without risk, in terms of morbidity and mortality. So it's the medication that is most often offered: many drugs have been proposed, a direct result of the multiplicity of neurotransmitter systems implicated. However, in the vast majority of cases, this approach is disappointing not to say ineffective. The only exception is the tetrabenazine, marketed under the name of Xenazine®. Empirically, neurologists specializing in pathology of the movement are almost unanimous: its efficiency is very good, with good tolerance. Some preliminary studies have reinforced this impression. However, their level of evidence remains low and that is why the investigators propose to implement a prospective multicenter clinical trial, double-blind with placebo which will include two groups of 27 patients.
Conditions
- Tardive Dyskinesia
Interventions
TetrabenazineDrug
Treatment with tetrabenazine consists in: * 5-week titration to a maximum dose of 200 mg / day * 5 weeks at stable dose * 2 weeks in wash-out The treatment will be blinded for patients and investigators
PlaceboDrug
Treatment with placebo consists in: * 5-week titration to a maximum dose of 200 mg / day * 5 weeks at stable dose * 2 weeks in wash-out The treatment will be blinded for patients and investigators
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in ESRS: Extrapyramidal Symptoms Rating ScaleTime frame: 10 weeks after randomization
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
CH Aix en Provence
Aix-en-Provence, France
CHU Bordeaux
Bordeaux, France
CHU Caen
Caen, France
CHU Clermont-Ferrand
Clermont-Ferrand, France
CHRU Lille
Lille, France
CHU Limoges
Limoges, France
CH des Charpennes
Lyon, France
AP-HM Hopital de la Timone
Marseille, France
CHU Montpellier
Montpellier, France
CHU Nantes
Nantes, France
CHU Nice
Nice, France
CHRU de Nimes
Nîmes, France
CHU Saint Antoine
Paris, France
CHU Poitiers
Poitiers, France
CHU de Rennes
Rennes, France
CHU Rouen
Rouen, France
CHU Strasbourg
Strasbourg, France
CHU Toulouse
Toulouse, France
CHU Amiens
Amiens, Picardie, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.